We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Study Reveals Mechanism Protecting UTI Bacteria from Nitric Acid Damage

By LabMedica International staff writers
Posted on 08 Nov 2016
A team of molecular microbiologists has identified the enzyme cytochrome bd-I oxidase as promoting urinary tract infections by being of critical importance in protecting E. More...
coli bacteria from the effects of nitric oxide generated by the host's immune response.

Nitric oxide (NO) is a toxic free radical produced by neutrophils and macrophages in response to infection. Uropathogenic Escherichia coli (UPEC) generate a variety of defence mechanisms in response to NO, including direct NO detoxification, iron-sulphur cluster repair, and the expression of the NO-tolerant cytochrome bd-I respiratory oxidase.

Investigators at the University of Kent (United Kingdom) and colleagues at the University of Queensland (Brisbane, Australia) quantified the relative contribution of these systems to UPEC growth and survival during infection.

They reported in the October 21, 2016, online edition of the journal Scientific Reports that while UPEC have acquired a host of specialized mechanisms to evade NO-based stresses, the cytochrome bd-I respiratory oxidase was the main contributor to NO tolerance and host colonization under microaerobic conditions. Since cytochrome bd-I is absent in humans, drugs designed to target this enzyme would be less likely to be toxic to human cells.

Related Links:
University of Kent
University of Queensland


New
Gold Member
Aspiration System
VACUSAFE
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Rapid Sepsis Test
SeptiCyte RAPID
New
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.